Company Profile
Profil emiten IDX — keuangan, direksi, komisaris, anak usaha
Indofarma Tbk.
INAF
Sector: Healthcare
Industry: Pharmaceuticals
Sub Sector: Pharmaceuticals & Health Care Research
Sub Industry: Pharmaceuticals
Live quote
tidak tersedia
tidak tersedia
Highlight Keuangan (2026 Q2) (In Rp)
EPS
-21
ROE
8,95%
ROA
-12,97%
Book Value
-239
Net Income
-33,13 M
Total Sales
79,04 M
Total Assets
510,83 M
DER
-1.69x
Struktur Pemegang Saham (>1%)
Free Float Information
Saham tersebar di publik
5,60%
80,66%
Tentang Perusahaan
PT Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk (the Company) was established based on Deed No. 1 dated January 2, 1996 as amended by Deed No. 134 dated January 26, 1996 both of Notary Sutjipto, SH. PT. Indofarma, Tbk began as medicine factory well known as "Pabrik Obat Manggarai". Then take over by Japan's Government from Nederland's Government on 1942. On 1950 the Indonesian Government acquisited the factory by Department of Health and functioned as center of pharmacy production for its department. On 1979 the name changed to be Department of Health Center of Pharmacy Production as non Profit institution as main assignment to produced medicine for public service. Then the Company changed the name as PT. Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk.
Produk & Lini Bisnis
The Company engage activities : a. Producing pharmaceutical raw and indirect materials, and chemical materials including agrochemical by itself or under license or contract with other partiesb. Producing of finished goods such as essential medicine, generic medicine, branded medicine, traditional medicine, cosmetics, medical devices, diagnostics and contraceptives. The Company also produces food products or any those related with health care and health improvement including animal food products. The Company produces such goods by itself or under license or contract with other parties.c. Producing packaging materials, machinery and equipment and infrastructure related to pharmaceutical industry or other industries.
Dewan Direksi
YA
Yeli Andriani
President Director
AP
Andi Prazos
Director
Dewan Komisaris
DA
Didi Agus Mintadi
President Commissioner
TW
Teddy Wibisana
Independent Commissioner
Anak Usaha & Afiliasi
| Nama | Domisili | % |
|---|---|---|
| PT Indofarma Global Medika Distribution and trading of pharmaceutical products |
Jakarta | 99.99% |
Trend Keuangan (5 periode terakhir)
— hover bar untuk detail
Total Sales
Net Income (+)
Net Income (-)
2025 Q2
EPS -28
ROE 10,79%
2025 Q3
EPS -55
ROE 19,02%
2025 Q4
EPS -25
ROE 11,03%
2026 Q1
EPS -10
ROE 4,24%
2026 Q2
EPS -21
ROE 8,95%
Laporan Keuangan Historis (5 Periode Terakhir) (In Rp)
| Periode | Total Sales | Net Income | Total Assets | Total Equity | EPS | ROE | DER |
|---|---|---|---|---|---|---|---|
| 2026 Q2 | 79,04 M | -33,13 M | 510,83 M | -740,07 M | -21 | 8,95% | -1.69x |
| 2026 Q1 | 53,33 M | -7,58 M | 489,67 M | -714,52 M | -10 | 4,24% | -1.69x |
| 2025 Q4 | 151,55 M | -77,99 M | 535,99 M | -706,94 M | -25 | 11,03% | -1.76x |
| 2025 Q3 | 133,74 M | -127,09 M | 581,56 M | -890,94 M | -55 | 19,02% | -1.65x |
| 2025 Q2 | 67,03 M | -43,55 M | 559,64 M | -807,40 M | -28 | 10,79% | -1.69x |
Trend Harga Penutupan & Book Value — hover titik untuk detail
Close Price
Book Value
2025 Q2
Close 126
BV -261
ROA -15,56%
2025 Q3
Close 126
BV -287
ROA -29,14%
2025 Q4
Close 126
BV -228
ROA -14,55%
2026 Q1
Close 126
BV -231
ROA -6,19%
2026 Q2
Close 126
BV -239
ROA -12,97%
History Harga Penutupan & Book Value
| Tahun | Qrt | Close Price (Rp) | Book Value (Rp) | ROA |
|---|---|---|---|---|
| 2026 | 2 | 126 | -239 | -12,97% |
| 2026 | 1 | 126 | -231 | -6,19% |
| 2025 | 4 | 126 | -228 | -14,55% |
| 2025 | 3 | 126 | -287 | -29,14% |
| 2025 | 2 | 126 | -261 | -15,56% |
Data diperbarui pada: 2026-05-07 12:26:50